EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients

Wenxi Yu, Miaoli Sun, Wei Wang, Zan Shen, Yonggang Wang, Hongtao Li

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08592-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Wenxi Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic …. Hauptthemen laut MEDLINE: Osteosarcoma, Neoadjuvant Therapy, Hemoglobins, Anemia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Anemia is relatively common in cancer patients, and is associated with poor survival in patients with various malignancies. However, how anemia would affect prognosis and response to neoadjuvant chemotherapy (NAC) in osteosarcoma (OS) is still without substantial evidence.

Methods

We retrospectively analysed 242 patients with stage II OS around the knee joint in our institute. Changed hemoglobin (Hb) levels (before and after NAC) were recorded to assess the prognostic value in DFS (disease-free survival) and tumor response to NAC. Univariate and multivariate analyses were conducted to identify prognostic factors related with outcome in OS patients.

Results

The mean Hb level significantly decreased after NAC (134.5 ± 15.3 g/L vs. 117.4 ± 16.3 g/L). The percentage of mild (21%), moderate (4.2%) and severe (0%) anemia patients markedly increased after NAC: 41%, 24% and 4.1% respectively. There was higher percentage of ≥ 5% Hb decline in patients with tumor necrosis rate < 90% (141 out of 161), compared with those with tumor necrosis rate ≥ 90% (59 out of 81). Further univariate and survival analysis demonstrated that Hb decline had a significant role in prediction survival in OS patients. Patients with ≥ 5% Hb decline after NAC had an inferior DFS compared with those with < 5% Hb decline.

Conclusion

In osteosarcoma, patients with greater Hb decrease during neoadjuvant treatment were shown to have worse DFS and a poorer response to NAC than those without. Attempts to correct anemia and their effects on outcomes for osteosarcoma patients should be explored in future studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaNeoadjuvant TherapyHemoglobinsAnemiaBone NeoplasmsKnee JointHumansRetrospective StudiesMaleFemaleAdultPrognosisAdolescentYoung AdultChildDisease-Free SurvivalMiddle AgedMultivariate AnalysisChemotherapy, AdjuvantSeverity of Illness Index

Stichwörter der Autor:innen

AnemiaOsteosarcomaSurvivalTumor necrosis rate

Substanzen

Hemoglobins

Autor:innen und Institutionen

  • Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Department of Clinical Laboratory, Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Department of Clinical Laboratory, Jining No.1 People's Hospital, Jining, Shandong Province, People's Republic of China.
  • Department of General Medicine, Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
  • Department of Surgery, Affiliated Hospital of Chongqing Population and Family Planning Research Institute, Chongqing, People's Republic of China.
  • Department of Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. sirui666@163.com.

Zitieren

APA

Yu, W., Sun, M., Wang, W., Shen, Z., Wang, Y., & Li, H. (2024). Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08592-2

Vancouver

Yu W, Sun M, Wang W, Shen Z, Wang Y, Li H. Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08592-2

BibTeX
@article{Yu2024,
  author = {Yu, Wenxi and Sun, Miaoli and Wang, Wei and Shen, Zan and Wang, Yonggang and Li, Hongtao},
  title = {Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08592-2}
}
Kostenlos starten →